A Phase 2 interventional study of Placebo and CP-690,550 in Crohn's Disease, sponsored by Pfizer. Completed at 91 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-01-09.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Crohn Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Crohn Disease · Pfizer.
Among the 17 studies in Crohn Disease by Pfizer, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2012, is one of 9 in phase 2, and was the 8th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →None of the 17 studies in Crohn Disease by Pfizer is open now. The open studies under Crohn Disease, anywhere →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 1
First in 2002; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 180 across the 11 interventional studies, 1,431 across the 5 observational. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Crohn Disease by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or clinical remission (CDAI\<150) at Week 8.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: CP-690,550
Drug: CP-690,550
oral tablets twice daily
oral tablets twice daily
oral tablets twice daily
Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or Clinical Remission (CDAI Score Less Than [<]150) at Week 26
Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity.
Time frame: Week 26
Percentage of Participants With Clinical Response-100 or Clinical Remission at Weeks 4, 8, 12 and 20
Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Time frame: Weeks 4, 8, 12 and 20
Percentage of Participants Achieving Clinical Response-100 at Weeks 4, 8, 12, 20 and 26
Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Time frame: Weeks 4, 8, 12, 20 and 26
Percentage of Participants in Clinical Remission at Weeks 4, 8, 12, 20 and 26
Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Time frame: Weeks 4, 8, 12, 20 and 26
Percentage of Participants in Clinical Remission at Week 4, 8, 12, 20 and 26 Among Participants in Remission at Baseline of Maintenance Study
Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Time frame: Weeks 4, 8, 12, 20 and 26
Percentage of Participants in Sustained Clinical Remission (Defined as Being in Clinical Remission at Both Weeks 20 and 26) in the Maintenance Phase
Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Time frame: Weeks 20 and 26
Percentage of Participants With Sustained Clinical Response-100 (Defined as Having at Least a Clinical Response-100 at Both Weeks 20 and 26 From the A3921083 Baseline) in the Maintenance Phase
Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Time frame: Weeks 20 and 26
CDAI Score by Week
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity
Time frame: Baseline and Weeks 4, 8, 12, 20 and 26
Change From Baseline in CDAI Score by Week
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity
Time frame: Weeks 4, 8, 12, 20 and 26
Kaplan-Meier Estimate of the Rate of Time to Relapse
Time to relapse was defined as increase in CDAI of more than (\>)100 points from the maintenance phase baseline and a CDAI score of \>220 points, or an increase to or above the baseline CDAI score in A3921083. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Time frame: Weeks 4, 8 12, 20 and 26
Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 26 of the Maintenance Phase - Among Participants on Steroids at A3921084 Baseline
Clinical remission was a CDAI \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body eight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Time frame: Week 26
C-Reactive Protein (CRP) by Week
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Baseline and Weeks 4, 8, 12, 20 and 26
Change From Baseline in CRP by Week
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Weeks 4, 8, 12, 20 and 26
Fecal Calprotectin by Week
Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.
Time frame: Baseline and Weeks 8, 12 and 26
Change From Baseline in Fecal Calprotectin by Week
Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.
Time frame: Weeks 8, 12 and 26
Tofacitinib Plasma Concentration by Nominal Post-Dose Sampling Time and Tofacitinib Dose
Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.
Time frame: Pre-dose, 20 minutes, 40 minutes, 1 hour and 2 hours post-dose at Weeks 12 and 26/early termination visit
| Milestone | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Started | 59 | 60 | 61 |
| Completed | 27 | 32 | 38 |
| Not completed | 32 | 28 | 23 |
| Withdrew: Study terminated by sponsor | 1 | 0 | 1 |
| Withdrew: Other | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Does not meet entrance criteria | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 26 | 21 | 16 |
| Withdrew: Adverse event | 1 | 5 | 3 |
Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity.
| Percentage of participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or Clinical Remission (CDAI Score Less Than [<]150) at Week 26 | 38.10 (27.94 to 49.16) | 39.53 (29.39 to 50.46) | 55.81 (44.92 to 66.28) |
Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
| Percentage of participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 4 | 73.81 (63.16 to 82.62) | 74.42 (63.96 to 83.05) | 79.07 (68.98 to 86.96) |
| Week 8 | 66.67 (55.69 to 76.37) | 67.44 (56.64 to 76.95) | 58.14 (47.22 to 68.46) |
| Week 12 | 50.00 (39.12 to 60.88) | 55.81 (44.92 to 66.28) | 53.49 (42.64 to 64.08) |
| Week 20 | 40.48 (30.13 to 51.55) | 39.53 (29.39 to 50.46) | 51.16 (40.38 to 61.86) |
Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
| Percentage of participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 4 | 73.81 (63.16 to 82.62) | 72.09 (61.49 to 81.04) | 76.74 (66.45 to 85.02) |
| Week 8 | 66.67 (55.69 to 76.37) | 62.79 (51.88 to 72.75) | 58.14 (47.22 to 68.46) |
| Week 12 | 50.00 (39.12 to 60.88) | 55.81 (44.92 to 66.28) | 51.16 (40.38 to 61.86) |
| Week 20 | 38.10 (27.94 to 49.16) | 39.53 (29.39 to 50.46) | 51.16 (40.38 to 61.86) |
| Week 26 | 35.71 (25.77 to 46.74) | 37.21 (27.25 to 48.12) | 55.81 (44.92 to 66.28) |
Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
| Percentage of participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 4 | 52.38 (41.42 to 63.16) | 55.81 (44.92 to 66.28) | 58.14 (47.22 to 68.46) |
| Week 8 | 47.62 (36.84 to 58.58) | 48.84 (38.14 to 59.62) | 39.53 (29.39 to 50.46) |
| Week 12 | 33.33 (23.63 to 44.31) | 46.51 (35.92 to 57.36) | 34.88 (25.14 to 45.75) |
| Week 20 | 30.95 (21.52 to 41.84) | 32.56 (23.05 to 43.36) | 39.53 (29.39 to 50.46) |
| Week 26 | 28.57 (19.43 to 39.35) | 37.21 (27.25 to 48.12) | 41.86 (31.54 to 52.78) |
Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
| Percentage of participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 4 | 72.00 (57.42 to 83.68) | 78.57 (65.41 to 88.34) | 80.77 (67.23 to 90.34) |
| Week 8 | 64.00 (49.20 to 76.97) | 64.29 (50.42 to 76.50) | 50.00 (35.93 to 64.07) |
| Week 12 | 40.00 (26.53 to 54.77) | 64.29 (50.42 to 76.50) | 42.31 (28.86 to 56.71) |
| Week 20 | 36.00 (23.03 to 50.80) | 42.86 (29.87 to 56.67) | 46.15 (32.36 to 60.43) |
| Week 26 | 28.00 (16.32 to 42.58) | 39.29 (26.65 to 53.16) | 50.00 (35.93 to 64.07) |
Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
| Percentage of participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Percentage of Participants in Sustained Clinical Remission (Defined as Being in Clinical Remission at Both Weeks 20 and 26) in the Maintenance Phase | 21.43 (13.37 to 31.71) | 23.26 (14.98 to 33.55) | 39.53 (29.39 to 50.46) |
Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
| Percentage of participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Percentage of Participants With Sustained Clinical Response-100 (Defined as Having at Least a Clinical Response-100 at Both Weeks 20 and 26 From the A3921083 Baseline) in the Maintenance Phase | 33.33 (23.63 to 44.31) | 25.58 (16.95 to 36.04) | 51.16 (40.38 to 61.86) |
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity
| Score on a scale | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Baseline | 135.05 ± 69.83 | 127.23 ± 60.46 | 133.98 ± 63.31 |
| Week 4 | 168.24 ± 103.18 | 133.48 ± 89.94 | 143.45 ± 84.26 |
| Week 8 | 171.87 ± 109.18 | 149.78 ± 99.56 | 165.69 ± 95.46 |
| Week 12 | 181.38 ± 108.68 | 158.56 ± 119.41 | 152.93 ± 82.77 |
| Week 20 | 161.76 ± 91.65 | 151.74 ± 106.09 | 112.32 ± 85.47 |
| Week 26 | 137.05 ± 77.65 | 134.77 ± 80.22 | 110.77 ± 76.30 |
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity
| Score on a scale | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 4 | 33.17 ± 76.41 | 5.85 ± 69.52 | 11.02 ± 72.22 |
| Week 8 | 39.85 ± 83.68 | 20.32 ± 69.59 | 101.96 ± 101.96 |
| Week 12 | 52.81 ± 113.91 | 32.29 ± 88.35 | 24.07 ± 84.46 |
| Week 20 | 32.44 ± 96.18 | 36.83 ± 90.92 | -14.36 ± 78.58 |
| Week 26 | 1.50 ± 93.91 | 17.36 ± 79.81 | -16.35 ± 75.65 |
Time to relapse was defined as increase in CDAI of more than (\>)100 points from the maintenance phase baseline and a CDAI score of \>220 points, or an increase to or above the baseline CDAI score in A3921083. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
| Percent Probability | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 4 (n=35,38,38) | 14.58 (8.42 to 22.37) | 7.14 (3.15 to 13.34) | 11.63 (6.30 to 18.73) |
| Week 8 (n=32,35,32) | 21.90 (14.27 to 30.60) | 14.47 (8.35 to 22.21) | 23.51 (15.73 to 32.21) |
| Week 12 (n=24,30,27) | 39.18 (29.40 to 48.80) | 26.69 (18.32 to 35.77) | 31.09 (22.19 to 40.38) |
| Week 20 (n=19,22,23) | 51.85 (41.33 to 61.37) | 39.11 (29.35 to 48.74) | 38.95 (29.16 to 48.60) |
| Week 26 (n=1,1,2) | 69.59 (48.73 to 83.29) | 50.69 (38.96 to 61.27) | 43.31 (32.60 to 53.54) |
Clinical remission was a CDAI \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body eight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
| Percentage of participants | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 26 of the Maintenance Phase - Among Participants on Steroids at A3921084 Baseline | 16.67 (4.52 to 38.55) | 27.27 (10.48 to 51.08) | 33.33 (17.20 to 53.17) |
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
| milligram per liter (mg/L) | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Baseline | 8.08 ± 13.88 | 7.08 ± 10.83 | 8.59 ± 16.43 |
| Week 4 | 16.08 ± 24.62 | 8.04 ± 17.36 | 7.62 ± 15.03 |
| Week 8 | 15.80 ± 28.98 | 8.03 ± 10.86 | 7.24 ± 16.48 |
| Week 12 | 15.49 ± 17.80 | 8.19 ± 11.75 | 5.57 ± 13.52 |
| Week 20 | 15.10 ± 20.37 | 10.07 ± 14.56 | 6.52 ± 18.26 |
| Week 26 | 27.70 ± 41.76 | 13.00 ± 13.65 | 3.57 ± 3.55 |
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
| milligram per liter (mg/L) | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 4 | 10.66 ± 19.47 | 0.84 ± 12.52 | -0.97 ± 10.81 |
| Week 8 | 10.33 ± 24.33 | 0.96 ± 9.80 | 1.29 ± 7.24 |
| Week 12 | 11.78 ± 17.85 | 2.36 ± 12.15 | 0.39 ± 3.66 |
| Week 20 | 11.48 ± 19.25 | 2.92 ± 14.86 | 0.91 ± 6.75 |
| Week 26 | 24.07 ± 40.90 | 6.62 ± 13.07 | 0.59 ± 3.75 |
Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.
| milligrams per kilogram (mg/kg) | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Baseline | 380.43 ± 296.24 | 351.39 ± 290.67 | 399.33 ± 346.98 |
| Week 8 | 440.81 ± 350.71 | 295.39 ± 272.25 | 283.76 ± 304.43 |
| Week 12 | 441.40 ± 336.51 | 351.59 ± 303.08 | 194.00 ± 208.50 |
| Week 26 | 939.11 ± 1037.39 | 500.18 ± 337.83 | 243.76 ± 219.04 |
Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.
| milligrams per kilogram (mg/kg) | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Week 8 | 69.22 ± 384.35 | -59.73 ± 216.36 | -123.95 ± 336.67 |
| Week 12 | 103.55 ± 311.15 | -1.81 ± 228.24 | -107.04 ± 259.68 |
| Week 26 | 579.10 ± 870.77 | 154.17 ± 349.49 | -33.75 ± 204.25 |
Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.
| nanograms per milliliter (ng/mL) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Week 12, 0 hours (n=43, 40) | 6.059 ± 7.4264 | 6.832 ± 5.7271 |
| Week 12, 20 minutes (n=45, 40) | 31.56 ± 21.904 | 58.53 ± 53.579 |
| Week 12, 40 minutes (n=47, 41) | 47.05 ± 23.904 | 85.23 ± 43.726 |
| Week 12, 1 hour (n=46, 42) | 46.84 ± 20.365 | 82.08 ± 33.779 |
| Week 12, 2 hour (n=44, 42) | 36.52 ± 14.810 | 69.79 ± 23.274 |
| Week 26/ET, 0 hours (n=43, 46) | 6.183 ± 13.673 | 9.510 ± 17.115 |
| Week 26/ET, 20 minutes (n=45, 48) | 40.98 ± 31.713 | 60.48 ± 51.084 |
| Week 26/ET, 40 minutes (n=46, 48) | 55.83 ± 44.421 | 85.66 ± 37.983 |
| Week 26/ET, 1 hour (n=45, 48) | 52.59 ± 42.291 | 86.25 ± 30.948 |
| Week 26/ET, 2 hours (n=44, 48) | 39.09 ± 22.606 | 64.15 ± 23.499 |
Collected over SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment (30 weeks). Non-SAEs were recorded from time of first dose of study treatment through last participant visit (30 weeks).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 7/59 (11.9%) | 28/59 (47.5%) |
| Tofacitinib 5 mg BID | — | 6/60 (10%) | 40/60 (66.7%) |
| Tofacitinib 10 mg BID | — | 8/61 (13.1%) | 35/61 (57.4%) |
| Event | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 3/59 | 0/60 | 2/61 |
| AnaemiaBlood and lymphatic system disorders | 1/59 | 0/60 | 0/61 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/59 | 0/60 | 0/61 |
| Cholecystitis acuteHepatobiliary disorders | 1/59 | 0/60 | 0/61 |
| Abortion inducedSurgical and medical procedures | 1/59 | 0/60 | 0/61 |
| Intestinal obstructionGastrointestinal disorders | 0/59 | 1/60 | 0/61 |
| Large intestine perforationGastrointestinal disorders | 0/59 | 1/60 | 0/61 |
| Anal abscessInfections and infestations | 0/59 | 1/60 | 1/61 |
| Clostridium difficile colitisInfections and infestations | 0/59 | 1/60 | 0/61 |
| Clostridium difficile infectionInfections and infestations | 0/59 | 1/60 | 0/61 |
| Event | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 10/59 | 11/60 | 7/61 |
| NasopharyngitisInfections and infestations | 4/59 | 11/60 | 5/61 |
| Urinary tract infectionInfections and infestations | 4/59 | 6/60 | 8/61 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/59 | 6/60 | 4/61 |
| Abdominal painGastrointestinal disorders | 2/59 | 5/60 | 4/61 |
| InfluenzaInfections and infestations | 2/59 | 5/60 | 3/61 |
| AnaemiaBlood and lymphatic system disorders | 0/59 | 3/60 | 5/61 |
| DiarrhoeaGastrointestinal disorders | 0/59 | 3/60 | 5/61 |
| HeadacheNervous system disorders | 2/59 | 4/60 | 2/61 |
| PyrexiaGeneral disorders | 2/59 | 2/60 | 4/61 |
The safety analysis set consisted of all participants who received at least 1 dose of study medication in this study.
| Age, Customized(Participants) | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Total |
|---|---|---|---|---|
| Less than or equal to (<=)18 years | 0 | 0 | 0 | 0 |
| Between 18 and 44 years | 34 | 44 | 40 | 118 |
| Between 45 and 64 years | 23 | 15 | 20 | 58 |
| More than or equal to (>=)65 years | 2 | 1 | 1 | 4 |
| Gender(Participants) | Placebo | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Total |
|---|---|---|---|---|
| Female | 32 | 30 | 24 | 86 |
| Male | 27 | 30 | 37 | 94 |
The record gives a start of Mar 2012, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib